Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

Tennessee’s Senate Bill 489, known as the Medical Cannabis Act, is scheduled to be discussed and potentially receive a vote ...

Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...

Kairos Pharma Ltd. has announced that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense lung cancer ...

Kairos Pharma (NYSE American: KAPA) announced that Cedars-Sinai Medical Center, through its academic partnership with the company, has received $600 ...

Kairos Pharma (KAPA) announced that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600, ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

There are so many benefits to taking vitamin C, but in order for it to work as well as it can, there are a few things to ...

Weight-loss drugs have helped many people lose excess weight, but for some, rapid weight loss comes with a hidden risk—the ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Reference: Frederik Duch Bromer, Andreas Lodberg, Marco Eijken, Christian Brix Folsted Andersen, Mathias Flensted Poulsen, ...